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ORIGINAL RESEARCH
Genetically Proxied Inhibition of Coagulation 
Factors and Risk of Cardiovascular Disease: 
A Mendelian Randomization Study
Shuai Yuan , MB, MSc; Stephen Burgess, PhD; Mike Laffan, PhD; Amy M. Mason , PhD; 
Martin Dichgans , PhD; Dipender Gill , PhD*; Susanna C. Larsson , PhD*
BACKGROUND: We conducted Mendelian randomization analyses investigating the linear associations of genetically proxied 
inhibition of different coagulation factors with risk of common cardiovascular diseases.
METHODS AND RESULTS: Genetic instruments proxying coagulation factor inhibition were identified from genome- wide asso-
ciation studies for activated partial thromboplastin time and prothrombin time in BioBank Japan (up to 58 110 participants). 
Instruments were identified for 9 coagulation factors (fibrinogen alpha, beta, and gamma chain; and factors II, V, VII, X, XI, 
and XII). Age- and sex- adjusted estimates for associations of the instruments with the outcomes were derived from UK 
Biobank and the FinnGen, CARDIoGRAMplusC4D (Coronary Artery Disease Genome- wide Replication and Meta- analysis), 
and MEGASTROKE consortia with numbers of incident and prevalent cases of 820 to 60 810. Genetically proxied inhibition of 
fibrinogen alpha, beta, and gamma chain, factor II, and factor XI were associated with reduced risk of venous thromboembo-
lism (P<0.001). With the exception of fibrinogen beta and factor II, inhibition of these factors was also associated with reduced 
risk of any ischemic stroke and cardioembolic stroke (P≤0.002). Genetically proxied inhibition of fibrinogen beta and gamma 
were associated with reduced large- artery stroke risk (P=0.001). There were suggestive protective associations of genetically 
proxied inhibition of factors V, VII, and X with ischemic stroke (P<0.05), and suggestive adverse associations of genetically 
proxied inhibition of factors II and XII with subarachnoid hemorrhage.
CONCLUSIONS: This study supports targeting fibrinogen and factor XI for reducing venous thromboembolism and ischemic 
stroke risk, and showed suggestive evidence that inhibition of factors V, VII, and X might reduce ischemic stroke risk.
Key Words: cardiovascular disease ■ coagulation ■ Mendelian randomization analysis ■ stroke ■ venous thromboembolism
By inhibiting components of the coagulation cas-cade, current anticoagulant therapies have proven effective for the prevention and treatment 
of venous thromboembolism (VTE).1,2 Anticoagulant 
therapies also reduce risk of other cardiovascular dis-
eases (CVDs) via effects on thrombosis,3– 6 with the 
adverse consequence of increasing risk of bleeding 
complications.4 However, given large differences in the 
role of individual coagulation factors in CVD subtypes, 
the efficacy and safety of anticoagulants targeting dif-
ferent coagulation factors remains largely unknown.7 
Recent meta- analyses of randomized clinical trials 
aimed to compare the health benefits, adverse effects, 
and cost- effectiveness across different anticoagulant 
drugs,6,8 thereby informing on optimized anticoagu-
lant treatment strategies. However, with the exception 
of approved antithrombotic agents such as vitamin 
K antagonists and factor IIa and factor Xa inhibitors, 
these questions could not be satisfactorily addressed 
because of insufficient availability of clinical trial data.8
By employing genetic variants as instrumental vari-
ables for coagulation factors in a Mendelian randomization 
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(MR) framework, the clinical effects of inhibition of dif-
ferent pathways of the coagulation cascade can be 
assessed using observational data. This approach can 
strengthen the causal inference in an exposure- outcome 
association by reducing residual confounding and re-
verse causality.9,10 Because genetic variants are ran-
domly allocated at conception, values of the exposure 
predicted by genetic variants are generally not correlated 
with other environmental factors, thus minimizing con-
founding. This process resembles the random assign-
ment of participants to treatment and control groups in a 
randomized controlled trial. In addition, alleles of genetic 
variants are fixed at birth and cannot be modified by the 
onset or progression of the disease, and thus, the MR 
design also diminishes risk of reverse causality.
Previous and ongoing clinical trials have aimed 
to assess effects of different anticoagulants on ath-
erosclerotic, thrombotic, and hemorrhagic CVDs. 
Anticoagulant drugs targeting a coagulation fac-
tor have been approved or are under investigation 
(Table 1). Clinical trials of oral anticoagulants often use 
intracranial hemorrhage, which includes intracerebral 
hemorrhage, subarachnoid hemorrhage, and epidural 
and subdural bleeds, as a measure for bleeding com-
plications. Given that the latter 2 of these bleeding 
complications are rare, intracerebral and subarachnoid 
hemorrhage were used to evaluate bleeding complica-
tions in the present investigation.
Here, we conducted a 2- sample MR study to com-
prehensively assess the potential effect of inhibiting 9 co-
agulation factors on risk of 9 thrombosis- related CVDs, 
including VTE, ischemic stroke and its etiologic subtypes, 
coronary artery disease, peripheral arterial disease, and 
intracerebral and subarachnoid hemorrhage. Secondary 
outcomes included heart failure, atrial fibrillation, aortic 
valve stenosis, and abdominal aortic aneurysm.
METHODS
Study Design
For coagulation factors involved in cell- based coagula-
tion cascade (Figure 1),11 we identified genetic proxies 
as single- nucleotide polymorphisms (SNPs) associ-
ated with activated partial thromboplastin time (aPTT) 
or prothrombin time (PT) and located within the gene 
region of the corresponding factor. We only used cis- 
variants (variants in the relevant coding gene region) 
as genetic proxies. To explore whether the effects are 
target specific, we also selected SNPs associated 
with aPTT or PT and examined their associations with 
outcomes in supplementary analyses. Summary- level 
data for aPTT and PT were obtained from BioBank 
Japan on 37 767 and 58 110 individuals, respectively.12 
Genetic instruments were identified for the 9 coagula-
tion factors, aPTT, and PT listed in Table 1 (there were 
no suitable SNPs for factor VIII and IX in their coding 
gene region). Outcome data were obtained from UK 
Biobank13 and the FinnGen,14 MEGASTROKE,15 and 
CARDIoGRAMplusC4D (Coronary Artery Disease 
Genome- wide Replication and Meta- analysis)16 con-
sortia. All studies had obtained ethical approval, and 
participants had given informed consent.
Genetic Instrument Construction
We constructed a genetic instrument consisting of 
SNPs associated with aPTT or PT at P<5×108. For 
coagulation factors in the common pathway (ie, fac-
tors II, V, and X), the weights of genetic instruments 
from the association with PT were applied because no 
SNP associated with aPTT was identified at P<5×10- 8. 
Independent SNPs (r2<0.01 and clumping window 
>10 000) within the coding gene region of the corre-
sponding coagulation factor were used as instrumen-
tal variables. Linkage disequilibrium r2 and clumping 
window were estimated based on 1000 Genomes link-
age disequilibrium reference panel (with only European 
population) and were obtained using the ld_matrix 
CLINICAL PERSPECTIVE
What Is New?
• Genetically proxied inhibition of fibrinogen 
alpha, beta, and gamma chain and factors II 
and XI were associated with reduced risk of ve-
nous thromboembolism.
• With the exception of fibrinogen beta and fac-
tor II, inhibition of these factors was also associ-
ated with reduced risk of any ischemic stroke 
and cardioembolic stroke.
• Genetically proxied inhibition of fibrinogen alpha 
and gamma were associated with reduced 
large- artery stroke risk.
What Are the Clinical Implications?
• The present Mendelian randomization study 
supports the efficacy of anticoagulants target-
ing fibrinogen, factor II, and factor XI in treating 
venous thromboembolism and revealed poten-
tial applications of inhibition of fibrinogen and 
factor XI for lowering risk of ischemic stroke, 
particularly cardioembolic stroke.
• Increased bleeding risk accompanied by these 
anticoagulants needs to be carefully assessed 
in further studies.
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command in the TwoSampleMR package.17 SNPs in 
linkage disequilibrium within a particular window were 
pruned, and the SNP with the lowest P value was re-
tained. The SNPs used as instrumental variables are 
shown in Table S1.
Outcome Sources
The UK Biobank study13 was used to estimate genetic as-
sociation with 10 CVDs, including the 6 major outcomes 
(VTE, ischemic stroke, coronary artery disease, periph-
eral arterial disease, and intracerebral and subarachnoid 
hemorrhage), among 367  643 adults (37– 73  years of 
age at baseline) of European ancestry after exclusion of 
relatedness of third degree or higher, low genotype call 
rate (≥3 SDs from the mean), and excess heterozygo-
sity. The participants were followed until March 31, 2017, 
or the date of death (recorded until February 14, 2018) 
with a median follow- up of 8.0  years. CVD diagnosis 
was based on electronic health records, hospital pro-
cedure codes, and self- reported information validated 
by interview with a nurse (Table S2). Clinical outcomes 
were not adjudicated by independent committee by pre-
defined criteria. Beta coefficients and standard errors of 
the genetic associations with CVD were calculated using 
Figure 1. Coagulation factors involved in cell- based coagulation cascade.
Activated partial thromboplastin time is used to evaluate the coagulation factors Ⅻ, Ⅺ, Ⅸ, Ⅷ, Ⅹ, Ⅴ, Ⅱ, and Ⅰ. Prothrombin time 
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logistic regression with adjustment for age, sex, and 10 
genetic principal components.
Publicly available summary- level data were ob-
tained for VTE and hemorrhagic stroke from the 
FinnGen consortium,14 for ischemic stroke from the 
MEGASTROKE consortium,15 and for coronary artery 
disease from the CARDIoGRAMplusC4D consortium.16 
The FinnGen consortium R4 includes 6913 VTE cases, 
1224 intracerebral hemorrhage cases, 1019 subarach-
noid hemorrhage cases, and >163  500 noncases of 
Finnish descent. Association tests were adjusted for 
age, sex, 10 genetic principal components, and geno-
typing batch. The MEGASTROKE consortium includes 
34 271 ischemic stroke cases and 404 630 noncases of 
European ancestry, and 4373 large- artery stroke cases, 
5386 small- vessel stroke cases, and 7193 cardioem-
bolic stroke cases. The MEGASTROKE consortium 
had some participant overlap with the FinnGen con-
sortium, and therefore FinnGen was not used for anal-
yses of ischemic stroke. The CARDIoGRAMplusC4D 
consortium involves 60 801 individuals with coronary 
heart disease and 123 504 noncases (77% of partic-
ipants were of European ancestry). All SNPs used as 
instrumental variables for the coagulation factors were 
available in all outcome data sources. Diagnostic infor-
mation for outcomes in FinnGen and consortia is pre-
sented in Tables S3 and S4.
Statistical Analysis
The fixed- effects inverse- variance weighted method 
was used to assess the associations of coagulation 
factors with 10 CVDs (5 primary and 5 secondary out-
comes) in the main analysis.18 Estimates were combined 
from different data sources using the fixed- effects meta- 
analysis method. The invariance weighted method with 
random effects was used to estimate the association 
of genetically predicted aPTT and PT with CVDs. All 
odds ratios and 95% CIs of the CVD outcomes were 
scaled to a 1- second increase in aPTT and PT. The 
Bonferroni correction method was used to account for 
multiple testing. We deemed associations with P<0.001 
(where P=0.05/54 [6 primary outcomes and 9 coagula-
tion factors]) as strong evidence of causal associations. 
Associations with P<0.05 but >0.001 were treated as 
suggestive evidence of associations. Analyses were 
performed using the mrrobust package19 in Stata/
SE 15.0 (StataCorp, College Station, TX) and the 
MendelianRandomization20 and TwoSampleMR17 pack-
ages in R software 3.6.0 (R Foundation for Statistical 
Computing, Vienna, Austria).
Pleiotropy Assessment
To detect possible pleiotropic effects of used SNPs 
for coagulation factors, we searched used genetic 
instruments in PhenoScanner V2 (a database of 
human genotype- phenotype associations)21 to ob-
tain associated phenotypes at the genome- wide 
significance level. Pleiotropy could not be explored 
statistically using MR sensitivity analyses because 
of a limited number of SNPs for each coagulation 
factor.
Data Availability
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
RESULTS
Associations of coagulation factors with VTE and 
ischemic stroke and its subtypes are displayed in 
Figures 2 through 4. Other associations are displayed 
in Table 2. Genetically predicted prolonged aPTT was 
suggestively associated with heart failure, atrial fibril-
lation, and ischemic stroke, but not associated with 
other outcomes (Figure S1). There was no association 
between genetically predicted PT and cardiovascular 
outcomes (Figure S1).
Genetically proxied inhibition of the coagulation 
cascade via fibrinogen alpha, beta, and gamma 
chain and factors II and XI was significantly associ-
ated with reduced risk of VTE in the meta- analysis of 
data from UK Biobank and FinnGen (P<0.001). The 
odds ratios scaled to a 1- second increase in aPTT 
or PT were 0.04 (95% CI, 0.03– 0.06) for fibrinogen 
alpha chain, 0.51 (95% CI, 0.34– 0.77) for fibrinogen 
beta chain, 0.04 (95% CI, 0.03– 0.06) for fibrinogen 
gamma chain, 0.16 (95% CI, 0.08– 0.32) for factor II, 
and 0.15 (95% CI, 0.12– 0.19) for factor XI. Genetically 
proxied inhibition of fibrinogen alpha and gamma 
chain and factor XI was also significantly associ-
ated with lower risk of ischemic stroke in the meta- 
analysis of UK Biobank and MEGASTROKE data, 
and corresponding odds ratios were 0.36 (95% CI, 
0.25– 0.52), 0.37 (95% CI, 0.26– 0.53), and 0.72 (95% 
CI, 0.58– 0.88), respectively. With regard to subtypes 
of ischemic stroke, fibrinogen alpha and gamma and 
factor XI were associated with cardioembolic stroke 
(P<0.001). Fibrinogen alpha and gamma were further 
associated with large- artery stroke (P<0.001). There 
were suggestive protective associations (P<0.05) of 
genetically proxied inhibition of fibrinogen beta and 
factors V, VII, and X with risk of ischemic stroke, 
and suggestive adverse effects of genetically prox-
ied inhibition of factors II and XII on subarachnoid 
hemorrhage.
Phenotypes associated with variants used to 
proxy coagulation factor inhibition at the genome- 
wide significance level are displayed in Table  S5. 
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thrombosis- related phenotypes, such as self- 
reported deep vein thrombosis, pulmonary em-
bolism, and phlebitis and thrombophlebitis, in 
genome- wide association studies of European in-
dividuals. In addition, we found the effect allele of 
rs2059503 (inhibition of fibrinogen beta chain) to 
be associated with higher levels of aspartate trans-
aminase, a marker of liver function. The effect allele 
of rs2070850 (inhibition of factor II) was associated 
with lower levels of high- density lipoprotein choles-
terol, bone mineral density and height, and lower 
liability to self- reported hypertension. Rs2282686 
(inhibition of factor II) was also associated with bone 
mineral density. The effect allele of rs9332653 (inhi-
bition of factor V) was associated with lower blood 
protein levels, and the effect allele of 2 SNPs for 
factor XII inhibition was associated with increased 
height.
Figure 2. Genetically proxied inhibition of coagulation factors and venous thromboembolism 
(15 602 cases in UK Biobank and 6913 cases in FinnGen) in the main analysis.
FGA indicates fibrinogen alpha chain; FGB, fibrinogen beta chain; FGG, fibrinogen gamma chain; IS, 
ischemic stroke; OR, odds ratio; UKBB, UK Biobank; and VTE, venous thromboembolism. Combined 
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DISCUSSION
This MR study strengthens the evidence of causal as-
sociations of fibrinogen and factors II and XI with VTE. 
More importantly, we observed robust evidence that 
inhibition of fibrinogen and factor XI reduces the risk 
of ischemic stroke, particularly cardioembolic stroke. 
Additionally, we found suggestive evidence that inhibi-
tion of factors V, VII, and X might reduce the risk of 
ischemic stroke. These findings imply possible benefits 
of anticoagulant therapies targeting those coagulation 
factors in the prevention of ischemic stroke. We did 
not detect any significant associations of coagulation 
factors with other CVD outcomes, in contrast to evi-
dence from clinical trials on factor Xa22 and thrombin 
inhibitors.23 A possible increased risk of hemorrhagic 
stroke could not be excluded for other anticoagulants 
and requires further study. Inhibition of factor VII, for 
Figure 3. Genetically proxied inhibition of coagulation factors and ischemic stroke (4602 cases 
in UKBB and 34 272 cases in MEGASTROKE) in the main analysis.
FGA indicates fibrinogen alpha chain; FGB, fibrinogen beta chain; FGG, fibrinogen gamma chain; IS, 
ischemic stroke; OR, odds ratio; and UKBB, UK Biobank. Combined estimates were estimated using 
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example, may cause increased risk of severe intracra-
nial hemorrhage.24
Overall, our findings were consistent with previ-
ous studies on the role of different coagulation fac-
tors in venous thrombosis.25– 27 Identified protective 
effects of coagulant factor inhibition on ischemic 
stroke were also in agreement with meta- analysis 
of clinical trials,28 and recent MR studies on fac-
tor XI.29– 31 Notably, the present investigation went 
further to assess the effects of 9 coagulation factors 
on thrombosis and other CVD outcomes. Possible 
adverse effects of different anticoagulants should 
be considered further. As the CIs for the association 
with hemorrhagic stroke would still be compatible 
with clinically relevant risk increase, more evidence 
is needed to accurately estimate any potential im-
pact of different coagulation factors on bleeding risk. 
This could be achieved by MR studies with greater 
Figure 4. Genetically proxied inhibition of coagulation factors and subtypes of ischemic stroke 
(4373 large artery stroke, 5386 small vessel stroke and 7193 cardioembolic stroke cases from 
MEGASTROKE) in the main analysis.
FGA indicates fibrinogen alpha chain; FGB, fibrinogen beta chain; FGG, fibrinogen gamma chain; and OR, 



































































































 http://ahajournals.org by on A
pril 16, 2021
J Am Heart Assoc. 2021;10:e019644. DOI: 10.1161/JAHA.120.019644 9








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on A
pril 16, 2021
J Am Heart Assoc. 2021;10:e019644. DOI: 10.1161/JAHA.120.019644 10
Yuan et al Coagulation Factors and Cardiovascular Disease
statistical power (eg, larger number of hemorrhagic 
stroke cases) or other study designs.
Repurposing anticoagulant drugs for atheroscle-
rotic CVD has been proposed in many large trials, 
albeit with inconclusive findings.32,33 Specifically, ef-
fects of anticoagulants targeting factors II and X, such 
as dabigatran, rivaroxaban, apixaban, and edoxaban, 
on cardioembolic stroke have been identified. Our 
findings for factor X are compatible with the effects of 
previous clinical trials on the prevention of ischemic 
stroke but not with those on VTE,34 possibly attribut-
able to pleiotropic effects of the genetic variants we 
employed. The F10 locus is located near the protein 
Z– dependent protease inhibitor gene, which shows 
a strong and independent association with ischemic 
stroke.35 The discrepancy may also be related by our 
application of genetic proxies for coagulation factors 
that were identified in Eastern Asian ancestry popu-
lations to CVD outcomes in European- ancestry pop-
ulations. Effects of anti– factor XI drugs on prevention 
of venous thrombosis have been studied in late- 
stage trials.36 Given their potential protective effect 
on cardioembolic stroke highlighted in previous29,31 
MR studies as well as in our present work, whether 
such drugs can be used for cardioembolic stroke 
prevention may also warrant investigation in a clinical 
trial setting. In addition, and consistent with previous 
investigation, we also found evidence to support that 
factor VII may represent a therapeutic target for isch-
emic stroke.37 Phenome- wide association studies 
on genetically proxied inhibition of coagulation fac-
tors represents a further approach to investigate the 
broad repurposing potential and adverse effect pro-
file of anticoagulant drug classes.38 Current evidence 
on the role of fibrinogen is conflicting, with previous 
studies identifying relationships with both increased 
and decreased risk of venous thrombosis.39,40 A 
recent MR study revealed that elevated fibrinogen 
gamma levels (based on 16 genetic instruments) and 
total fibrinogen levels (based on 75 genetic instru-
ments) were associated with a decreased risk for 
thrombosis.40 Our findings, however, did not sup-
port these associations. The reasons underlying this 
discrepancy are unclear and may be related to our 
scaling of variant effects based on their relation to 
aPTT, while the previous study considered circulating 
fibrinogen levels.40 We note that coagulation factors 
may alter the risk of thrombosis by mechanisms that 
do not affect the aPTT, such as factor XIII activation 
and related fibrinolysis.41 In addition, we noticed that 
differences in the effects of 3 chains of fibrinogen on 
VTE. The fibrin clot is stabilized by activated factor 
XIII, which crosslinks gamma- gamma and gamma- 
alpha chains within the network.42 This crosslinking 
may explain a greater effect for variants at FGA and 
FGG as compared with FGB.
There are several strengths and limitations of the 
present study. The major merit is the MR design that 
reduced the bias introduced by unobserved confound-
ing and reverse causation, and therefore strengthened 
the causal inference in the associations of 9 coagula-
tion factors with CVD. In addition, associations were 
concordant in 2 independent data sources, which im-
proved the robustness of our findings. We indirectly 
measured the effects of genetically proxied inhibition 
of coagulation factors through the association of ge-
netic variants with either aPTT or PT, which limited the 
comparability of the magnitude of the associations of 
different coagulation factors with the outcomes. Future 
studies can adopt an alternative approach to identify 
variants by their relation to coagulation factor levels. As 
mentioned above, it may also be that the coagulation 
factors are exerting affects unrelated to aPTT or PT, 
which we are unable to measure. Another limitation is 
that association estimates using robust MR methods 
were not feasible because of a limited number of SNPs 
identified for each coagulation factor. Although we can-
not rule out that our results might have been affected 
by potential pleiotropic effects, most incorporated vari-
ants were not strongly associated with established risk 
factors for VTE, stroke, or other CVDs. However, one 
of the SNPs for factor II and both SNPs for factor XII 
were associated with height, which is inversely asso-
ciated with coronary artery disease, ischemic stroke, 
and peripheral artery disease and positively associated 
with VTE and atrial fibrillation.43 Thus, the association 
between genetically proxied inhibition of factor XII and 
coronary artery disease may be driven by pleiotropic 
effects related to height. Interestingly, some of the 
other associations may also be informative of poten-
tial adverse effects, such as related to bone mineral 
density and fracture risk, for example.44 Another limita-
tion was that the negative findings might be attributed 
by lack of sufficient statistical power to detect an ef-
fect. However, it is impossible to estimate power in the 
present MR, as the unit of the effect of used SNPs 
for anticoagulation factors was not in SD units and the 
information on SD was unknown in the genome- wide 
association studies we used. In general, there are con-
cerns about performing post hoc power calculations 
(ie, after the analysis plan is fixed). The 95% CI for the 
estimates provides a useful indication of the plausible 
magnitude of causal effect based on the data available, 
and hence the extent to which findings are underpow-
ered. Studies with large sample size are warranted to 
verify the null associations.
CONCLUSIONS
The present MR study supports the efficacy of antico-
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treating venous thromboembolism and revealed poten-
tial applications of inhibition of fibrinogen and factor XI 
for lowering risk of ischemic stroke, particularly cardi-
oembolic stroke. We also noticed possible protective 
associations of genetically proxied inhibition of factors 
V, VII, and X with risk of ischemic stroke, which war-
rant further study. There was no significant evidence 
supporting effects on risk of other cardiovascular out-
comes related to the use of anticoagulants. However, 
increased bleeding risk accompanied by these anti-
coagulants needs to be carefully assessed in further 
studies.
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Table S1. Detailed information on genetic instruments for coagulation factors. 
 
Factor Name Indication rsID NEA EA EAF Beta SE p 
FI Fibrinogen alpha aPTT rs6050 C T 0.475 0.055 0.007 4.8E-14 
FI Fibrinogen beta aPTT rs2059503 A T 0.128 0.065 0.011 3.1E-09 
FI Fibrinogen gamma aPTT rs2066861 T C 0.491 0.059 0.007 7.3E-16 
FII Prothrombin PT rs2070850 T C 0.551 0.040 0.007 1.5E-09 
FV Proaccelerin or labile factor PT rs9332678 T A 0.596 0.079 0.006 1.3E-40 
FV Proaccelerin or labile factor PT rs6013 G T 0.085 0.209 0.011 1.9E-87 
FV Proaccelerin or labile factor PT rs2239853 T C 0.843 0.045 0.008 3.8E-08 
FVII Proconvertin or stable factor PT rs2774033 G A 0.061 0.450 0.014 1.0E-200 




aPTT rs56810541 T A 0.312 0.093 0.008 2.4E-28 
FXII Hageman factor aPTT rs4976649 A G 0.247 0.338 0.010 1.0E-200 
aPPT aPPT aPTT rs6013 T A 0.135 0.088 0.011 5.67E-16 
aPPT aPPT aPTT rs754549 G T 0.085 0.172 0.013 4.33E-39 
aPPT aPPT aPTT rs5030081 C T 0.399 0.059 0.008 3.92E-15 
aPPT aPPT aPTT rs1648717 A G 0.722 0.121 0.008 3.97E-49 
aPPT aPPT aPTT rs149893292 A G 0.505 0.059 0.007 4.31E-16 
aPPT aPPT aPTT rs12644950 G A 0.290 0.072 0.008 1.22E-18 
aPPT aPPT aPTT rs56810541 T A 0.688 0.093 0.008 2.40E-28 
aPPT aPPT aPTT rs4976649 G A 0.175 0.068 0.010 6.20E-12 
aPPT aPPT aPTT rs55730132 G C 0.690 0.225 0.008 4.18E-176 
aPPT aPPT aPTT rs7447593 A G 0.753 0.338 0.010 1.00E-200 
aPPT aPPT aPTT rs28696310 A G 0.337 0.052 0.008 8.66E-11 
aPPT aPPT aPTT rs687289 A G 0.739 0.080 0.009 2.35E-18 
aPPT aPPT aPTT rs4962113 A G 0.726 0.079 0.008 5.77E-21 
aPPT aPPT aPTT rs7870707 T C 0.376 0.080 0.008 2.82E-26 
aPPT aPPT aPTT rs9411466 A G 0.547 0.127 0.007 8.81E-68 
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aPPT aPPT aPTT rs7895470 G C 0.242 0.053 0.009 2.51E-09 
aPPT aPPT aPTT rs7962629 G A 0.925 0.083 0.014 1.39E-09 
aPPT aPPT aPTT rs1801690 C G 0.104 0.086 0.012 4.68E-13 
PT PT PT rs7521392 G A 0.410 0.038 0.006 1.22E-10 
PT PT PT rs1208134 T C 0.071 0.105 0.012 5.59E-20 
PT PT PT rs12022009 G T 0.399 0.082 0.006 1.03E-41 
PT PT PT rs6013 G T 0.085 0.209 0.011 1.85E-87 
PT PT PT rs2239853 T C 0.843 0.045 0.008 3.78E-08 
PT PT PT rs1313566 G A 0.436 0.037 0.006 3.33E-10 
PT PT PT rs2066861 T C 0.509 0.054 0.006 2.04E-20 
PT PT PT rs2481942 A G 0.060 0.090 0.014 2.65E-11 
PT PT PT rs927826 T G 0.276 0.059 0.007 4.37E-19 
PT PT PT rs10761723 C T 0.493 0.041 0.006 4.42E-12 
PT PT PT rs2070850 T C 0.449 0.040 0.007 1.48E-09 
PT PT PT rs57799948 C T 0.121 0.102 0.011 4.43E-22 
PT PT PT rs73576876 G A 0.280 0.060 0.007 1.68E-19 
PT PT PT rs2181540 T C 0.059 0.412 0.013 1.00E-200 
PT PT PT rs867186 G A 0.959 0.150 0.015 5.64E-24 
 
aPTT, indicates activated partial thromboplastin time; EA, effect allele; EAF, effect allele frequency; FGA, fibrinogen alpha-chain; FGB, fibrinogen beta-chain; FGG, 
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Table S2. Definitions for cardiovascular disease outcomes in UK Biobank. 
 
Outcome Cases Controls ICD-9 diagnosis ICD-10 diagnosis OPCS procedure 
Self-
report† 
Coronary artery disease 29 278 338 308 410, 411, 412, 414.0, 414.8, 414.9 
I21, I22, I23, I24, I25.1, I25.2, 
I25.5, I25.6, I25.8, I25.9 
K40, K41, K42, K43, K44, K45, 




Heart failure 6712 360 874 
402.01, 402.11, 402.91, 404.01, 
404.11, 404.91, 404.03, 404.13, 
404.93, 428 
I11.0, I13.0, I13.2, I50  20002 
Atrial fibrillation 16 945 350 641 427.3 I48  20002 
Aortic valve stenosis 2244 365 342  I35.0, I35.2  20002 
Abdominal aortic aneurysm 1094 366 492 441.3, 441.4 I71.3, I71.4 L19.4, L19.5 20002 
Intracerebral hemorrhage 1064 366 522 431 I61  20002 
Subarachnoid hemorrhage 1084 366 502 430 I60  20002 
Ischemic stroke 4602 362 984 434, 436 I63, I64  20002 
Venous thromboembolism 15 602 353 489 
415.1, 451.1, 452, 453.0, 453.4, 
453.9 
I26, I80.1, I80.2, I81, I82.0 L90.2 20002, 6152 
Peripheral arterial disease 3415 364 171 443.8, 443.9 I73.8, I73.9  20002 
 
ICD, International Classification of Disease; OPCS, Office of Population Censuses and Surveys Classification of Surgical Operations and Procedures. 
Follow-up for incident cases was until March 31, 2017 and date of death was recorded until February 14, 2018. 
†Numbers refer to data fields used in UK Biobank: 6150/6152 = Health condition diagnosed by doctor (self-reported); 6177 = Medication for health condition (self-reported); 20002 = 
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Table S3. Definitions for cardiovascular disease outcomes in FinnGen consortium. 
 
Outcomes Cases Controls 
Diagnostical information 
ICD-10 ICD-9 ICD-8 
Intracerebral hemorrhage 1224 163 533 I61 431 431 
Subarachnoid hemorrhage 1019 163 508 I60 430 430 
Venous thromboembolism 6913 169 986 
O882/I80/O871/I26, excluding 
I800 
415/451, excluding 4510 450|451|671|6739 
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Table S4. Definitions for cardiovascular disease outcomes in consortia 
. 
Outcomes Consortium Cases Controls Diagnostical information 
Coronary artery disease CARDIoGRAMplusC4D 60 801 123 504 
Case status was defined by an inclusive coronary artery disease diagnosis (for 
example, myocardial infarction, acute coronary syndrome, chronic stable angina or 
coronary stenosis of >50%). 
Any ischemic stroke MEGASTROKE 60 341 NA The stroke cases were defined as rapidly developing signs of focal (or global) 
disturbance of cerebral function, lasting more than 24 hours or leading to death 
with no apparent cause other than that of vascular origin. Any ischemic stroke was 
defined by all stroke cases except for intracerebral hemorrhage. Any ischemic 
stroke included large artery ischemic stroke, cardioembolic ischemic stroke, and 
small vessel ischemic stroke according to the Trial of Org 10,172 in Acute Stroke 
Treatment criteria, and also included ischemic stroke of undefined subtype. 
Large artery stroke MEGASTROKE 6688 146 392 
Small vessel stroke MEGASTROKE 11 710 192 662 
Cardioembolic stroke MEGASTROKE 9006 204 570 
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Table S5. Phenotypes associated with used SNPs at genome-wide significance†. 
 
Factor SNP EA Associated phenotype Beta 
FI rs6050 T Gamma fibrinogen levels NA 
   Plasma fibrin D dimer levels NA 
   Pulmonary embolism -0.001 
   Blood clot in the leg -0.003 
   Phlebitis and thrombophlebitis -0.001 
   Venous thrombosis NA 
FI rs2059503 T Aspartate transaminase 0.020 
FI rs2066861 C Gamma fibrinogen levels NA 
   Self-reported DVT -0.003 
   Pulmonary embolism -0.001 
   Phlebitis and thrombophlebitis -0.001 
FII rs2070850 C High-density lipoprotein cholesterol -0.053 
   Height -0.016 
   Forced vital capacity -0.020 
   Heel bone mineral density -0.029 
   Self-reported hypertension 0.009 
FV rs9332678 A None  
FV rs6013 T None  
FV rs2239853 C None  
FVII rs2774033 A None  
FX rs474810 C Factor VII clotting activity NA 
   Factor X antigen NA 
FXI rs56810541 A Self-reported DVT -0.003 
   Self-reported pulmonary embolism -0.001 
   Phlebitis and thrombophlebitis -0.001 
FXI rs4253421 A Self-reported pulmonary embolism -0.003 
   Self-reported DVT -0.004 
FXII rs4976649 G Height 0.013 
 
†Pleiotropic phenotypes were obtained by a search in http://www.phenoscanner.medschl.cam.ac.uk/.  
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Figure S1. Genetically predicted aPTT and PT in relation to cardiovascular disease. 
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